MedTrace Logo

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-08-18

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or feet (palmoplantar psoriasis).

Conditions

Interventions

BIOLOGICAL

Etanercept

Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.

OTHER

Placebo injections

Placebo injections twice weekly for 12 weeks.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Gerald D Weinstein, M.D. · University of California, Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585650 on ClinicalTrials.gov